Bioventix PLC Sustainability Reports

Bioventix PLC specializes in the development and commercial supply of high-affinity sheep monoclonal antibodies (SMAs) for use in clinical diagnostics blood testing. Its portfolio includes antibodies targeting heart disease, cancer, fertility, and thyroid conditions.

Sector: Professional & technical services

Country: United Kingdom

Exchange: London Stock Exchange (AIM)

LEI: 213800225MHX7LZQY108

FIGI: BBG001T7VPR1

7 reports from 2019 to 2025

• Bioventix PLC 2025 Annual Report and Financial Statements
• Bioventix PLC 2024 Annual Report and Financial Statements
• Bioventix PLC 2023 Annual Report and Financial Statements
• Bioventix PLC 2022 Annual Report and Financial Statements
• Bioventix PLC 2021 Annual Report and Financial Statements